Skip to main content

Moat Ross's Form 4 filing

Kiniksa Pharmaceuticals International, plc (KNSA) · filed Sep 4, 2024

Accession no.
0001415889-24-022854
Filed
Sep 4, 2024
Trade date
Jul 15-Sep 3, 2024
Filing delay
51 daysLate
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 8 derivative transactions. Open-market sales total $1.79M. It was filed 51 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Moat RossCIK 0001857177Officer (CHIEF COMMERCIAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 15, 2024Class A Ordinary ShareAGrant or awardAcquired+211$15.65+$3,302.1518,391Direct
Sep 1, 2024Class A Ordinary ShareMOption exerciseAcquired+4,089–F2–22,480Direct
Sep 1, 2024Class A Ordinary ShareFTax withholdingDisposed−1,393$26.74−$37,248.8221,087Direct
Sep 2, 2024Class A Ordinary ShareMOption exerciseAcquired+994–F2–22,081Direct
Sep 2, 2024Class A Ordinary ShareFTax withholdingDisposed−345$26.74−$9,225.321,736Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseAcquired+14,000$8.83+$123,62035,736Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseAcquired+29,730$11.10+$330,00365,466Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseAcquired+24,776$11.97+$296,568.7290,242Direct
Sep 3, 2024Class A Ordinary ShareSSaleDisposed−67,346$26.10F4−$1,757,730.622,896Direct
Sep 3, 2024Class A Ordinary ShareSSaleDisposed−1,160$27.12F5−$31,459.221,736Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 1, 2024Class A Ordinary ShareAGrant or awardAcquired+6,962$0.00$06,962Direct
Sep 1, 2024Class A Ordinary ShareAGrant or awardAcquired+36,100$0.00$036,100Direct
Sep 1, 2024Class A Ordinary ShareMOption exerciseDisposed−2,477$0.00$04,954Direct
Sep 1, 2024Class A Ordinary ShareMOption exerciseDisposed−1,612$0.00$04,833Direct
Sep 2, 2024Class A Ordinary ShareMOption exerciseDisposed−994$0.00$0994Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseDisposed−14,000$0.00$00Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseDisposed−29,730$0.00$018,534Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseDisposed−24,776$0.00$030,924Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Referenced by the price of 2 transactions in Table I.

F4

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.88 to $26.80. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $26.995 to $27.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)